Interleukin-15 (IL15) is a potential immunotherapeutic treatment for cancer. Caspy2 is an active zebra caspase for inducing apoptosis and immune response in murine tumors. In this study, we aim to evaluate the potential of gene therapy using IL15 and Caspy2 against the murine tumors. Plasmid expressing both Caspy2 and IL15 genes was constructed, encapsulated in DOTAP/cholesterol cationic liposome and injected intratumorally into the mice bearing CT26, B16-F10 and 4T1 carcinoma. We found that coexpression of IL15 and Caspy2 could significant inhibit tumor growth and prolong survival of the mice bearing CT26 or B16F10 tumor. A significant reduction in spontaneous lung metastasis was observed in the 4T1 tumor model. In CT26 model, the mice treated with IL15 and Caspy2 acquired a long-time protective immunity against the parental tumor cell rechallenge. Cytotoxic T lymphocytes and terminal deoxynucleotidyltransferase-mediated nick end labelling assays showed that the combination of capsy2 and IL15 could enhance both the apoptosis and immune response induction, which may account for its extraordinary antitumor effect. Furthermore, we showed that the observed tumor suppression by IL15 and Caspy2 concurred with the Caspy2-mediated downregulation of IL10 and upregulation of interferon-g and tumor necrosis factor-a. Our results therefore suggested that the combination regimen might be a novel and effective strategy for cancer treatment.
INTRODUCTION
Interleukin-15 (IL15), a member of the common gamma chain or 4-a-helix bundle family of cytokines is produced by a variety type of cells, but not by T cells.
1 IL15 has an important role in the development, homeostasis and function of memory CD8 þ T cells, natural killer (NK) cells and NK T cells. 2, 3 It also induces proliferation of naive CD8 þ , memory CD4 þ and CD8 þ T cells, and promoting development of the primary response of effector CD8 þ T cells. 4--6 IL15 has also demonstrated chemotactic activity towards CD4 þ and CD8 þ T cells. 7 In addition, IL15 can also upregulate production of tumor necrosis factor-a (TNF-a) and interferon-g (IFN-g) by NK and T-cells. 3, 8 The potential use of IL15 as a cancer immunotherapeutic agent has been investigated in several mouse cancer models. 9--13 IL15 is efficacious as a single agent in preclinical tumor models. However, combination therapy has had better success in treating cancer patients and applications combining IL15 with other therapies are likely to better benefit patients with cancer. 14, 15 A variety of strategies for gene therapy of cancer have currently shown remarkable efficacy, both in vitro and in vivo. 16 Triggering apoptosis and inducing specific immune response in cancer cells are two major approaches in anticancer gene therapies. 17, 18 Thus, the combination of apoptosis induction and active immunotherapy may be a new and potent strategy for cancer therapy. Indeed, researchers have applied this strategy to improve the therapeutic efficacy of cancer treatment. 19--21 In this study, we have analyzed the possible cooperative antitumor effects of Caspy2 and IL15 gene transfer in murine tumor models. Caspy2, a zebrafish protease, is an active caspase and shows similar homology to human caspase-5. A previous study has demonstrated that expression of Caspy2 could induce apoptosis in mammalian cells in vitro, which could be inhibited by general caspase inhibitors. 22 Our recent study indicated that Caspy2 could be an apoptosis inducer in vivo. In addition, a specific antitumor cellular immune response was elicited through CD8
þ T cells at the same time. 23 We presented here the first evidence that the enforced coexpression of IL15 and Caspy2 dramatically and additively inhibited tumor cell growth and metastasis in vivo. In addition, we showed that the IL15-and Caspy2-mediated tumor suppression is associated with the Caspy2-mediated downregulation of immunosuppressive cytokine, IL10. The enhanced antitumor activity is mainly through activated T-cell recruitment and inducement of apoptosis. The findings from this study suggest that the combination regimen should be very promising for the cancer treatment.
MATERIALS AND METHODS

Cells lines
Murine colon adenocarcinoma cell line CT26, murine melanoma cell line B16F10 and murine breast cancer cell line 4T1 were purchased from the American Type Culture Collection (ATCC, Rockville, MD) and maintained in DMEM or RPMI-1640 supplemented with 10% fetal bovine serum.
Plasmid construction
Caspy2 gene cloned to pcDNA3.1 þ expression vector (Invitrogen, Carlsbad, CA) was conserved by our laboratory as described previously. 23 PORF-hIL15 was purchased from InvivoGen (InvivoGen, San Diego, CA). A dual promoter plasmid, pVitro2 (InvivoGen) was utilized for the coexpression of caspy2 and IL15 gene. Caspy2 gene was amplified from existing pcDNA3.1-Caspy2 and the cDNA was inserted between the restriction sites SgrA I and Nhe I containing human ferritin light chain promoter and CMV enhancer. IL15 was amplified from pORF-hIL15 and inserted at the restriction sites EcoR V and Sal I under the human ferritin heavy chain promoter and SV40 enhancer. Also, expression vector for caspy2 or IL15 alone was constructed. An empty pVitro2 vector was used as control. The resulting plasmids were termed as pIL15-Caspy2, pCaspy2 and pIL15, respectively. Verification of the recombinant construct was performed by DNA sequencing. The plasmids were purified using Endo-free columns (Qiagen, Germantown, MD), following the instructions of the manufacturer.
Murine tumor models and treatment of established tumors
Animal studies were performed in accordance with institutional guidelines concerning animal use and care. Female C57BL/6 mice and female BALB/c mice (6--8 weeks) were purchased from the laboratory Animal Center of Sichuan University (Chengdu, Sichuan, China) and allowed to acclimate for 1 week before use.
About 2 Â 10 5 CT26 cells or 1 Â 10 5 B16F10 cells were inoculated subcutaneously in the right flank of each BALB/c mice or C57BL/6 mice, respectively. When the size of tumors reached B100 mm 3 , mice were randomly divided into the following five groups: 5% glucose (GS), pVitro2, pIL15, pCaspy2 and pIL15-Caspy2 (n ¼ 10), and the treatment was initiated. Cationic liposomes were used to enhance the transfection efficiency. Cationic liposome containing DOTAP in a 1:1 molar ratio with cholesterol (Avanti Polar Lipids, Alabaster, AL) was prepared as describe previously. 24 Cationic liposome--DNA complexes (DNA (10 mg) per liposome (50 mg) ¼ 1:5) were injected into each of four tumor quadrants three times weekly in a volume of 100 ml for a total of seven times. Tumors were measured 2-day interval with vernier calipers. The tumor volume was determined by the following formula: tumor volume (mm 3 ) ¼ length (mm) Â width (mm) 2 /2. Three days after the last injection, the animals were killed and tumor tissues were excised. The tumor tissues were paraffin-embedded or quickfrozen and sectioned for further pathological analysis. After observed definite curative effect in the first animal experiment, we repeated these two tumor models to investigate whether the treatment could prolong the survival of tumor bearing mice and preceded further studies.
To establish spontaneous metastasis model, 2 Â 10 5 4T1 breast carcinoma cells were injected into the right flank of each BALB/c mice, and this model can spontaneous formed pulmonary metastasis after 2 weeks. Two weeks after the implantation, mice were randomly allocated to five groups as described previously. Mice were treated with DNA--liposome complex three times weekly for total seven times. When the tumor volume reaches B2000 mm 3 , the animals were killed, and their lung tissues were excised. Tumor colonies on lung surfaces were counted under a dissecting microscope, and the lung tissues were paraffin-embedded and sectioned for further pathological analysis.
Assay for cytokine production within tumors
The cytokine production in tumors was determined 24 h after receiving two administrations as described previously. 25 Nonnecrotic tumors were harvested from the mice in the various treatment groups described previously for cytokine evaluation. TNF-a, IL10 and IFN-g levels were measured in the supernatant of tumor homogenates by a cytokine-specific ELISA kit.
In vitro cytotoxicity assay A lactate dehydrogenase release assay, as described previously, 13 was used to determine specific cytotoxicity mediated by cytotoxic T lymphocytes (CTLs). Lymphocytes were isolated from spleen of each mouse in CT26 model as described previously. 26 Lactate dehydrogenase was performed by using CytoTox 96 Non-Radioactive Cytotoxicity Assay kit (Promega, Madison, WI) with CT26 cells as target cells, according to manufacturer's instructions. The percent of cytotoxicity was calculated by the formula: % of cytotoxicity ¼ ((experimental releaseÀeffector spontaneous releaseÀ target spontaneous release)/(target maximum releaseÀtarget spontaneous release)) Â 100%. In the cytotoxicity inhibition assays, effector cells were pre-treated with mAb at room temperature for 30 min, washed and tested. MAbs used included anti-CD4 þ (10 mg ml À1 ), anti-CD8 þ (10 mg ml À1 ), anti-NK (10 mg ml À1 ) and anti-H-2 Kb/H-2 Db (50 mg ml À1 ) (BD Pharmingen, San Diego, CA). Control cytotoxicity assay was performed in the presence of control mAb (anti-H-2Dd) or isotype IgG.
Histological analysis
Immunofluorescence staining was used for detection and analysis of lymphocytes infiltrating into tumor in situ. Tumors were snap-frozen, and 8-mm sections were prepared in Tissue Tek (Sakura Finetek, Torrance, CA) for immunofluorescence analysis. Sections were blocked in 3% BSA for 30 min before staining with anti-CD8 þ monoclonal antibody (Cy5PE conjugate; eBioscience, San Diego, CA). Sections were washed three times between each reagent. Fluorescence was visualized, and images were captured with Olympus BX60 (Olympus, Tokyo, Japan).
To quantify proliferation index, expression of Ki67 was determined by immunohistochemical staining with goat anti-mouse antibody (Santa Cruz Biotechnology, Santa Cruz, CA). The percentage of Ki67-positive cells was counted in 10 random 0.159-mm 2 fields at Â 100 magnification. Terminal deoxynucleotidyltransferase-mediated nick end labelling (TUNEL) assay was performed for detecting fluorescence of apoptotic cells in situ using the TUNEL kit (Promega) following the manufacturer's protocol. Apoptotic cells were counted under a microscope ( Â 100) in randomly selected fields. Five to six random fields totaling at least 1000 tumor cells were counted per slide.
In vivo depletion of immune cell subsets
Immune cell subsets were depleted as previously described. 23 Briefly, BALB/c mice were injected intraperitoneally with anti-CD4 þ (clone GK1.5; rat IgG), anti-CD8 þ (clone 2.43; rat IgG), or anti-NK (clone PK136, rat IgG) monoclonal antibody with 500 mg kg À1 per mouse 1 day before treatment and then twice weekly for 2 weeks. Tumor size was measured 25 days after inoculation.
Tumor cells rechallenge
To determine whether surviving mice in CT26 model had developed a long-term immunological memory, the animals were divided into two groups (five mice each group) and rechallenged subcutaneously at the other flank with 2 Â 10 5 parental CT26 cells or irrelevant 4T1 cells, respectively.
Toxicity assessment
Possible side effects were observed through weight, appetite, diarrhea, life span and behavior until the mice were killed. Organs such as the heart, liver, spleen, lung and kidney were collected and made into 4 mm sections, which were stained with hematoxylin and eosin (H&E) and observed by two pathologists in a blinded manner under a microscope.
Statistical analysis SPSS 13.0 was used for statistical analysis. The statistical significance (p) of results in all of the experiments was determined by Student's t-test and ANOVA. Survival curves were compared by the log-rank test. The findings were regarded as significant if Po0.05.
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RESULTS
Coexpression of IL15 and Caspy2 significant inhibits tumor growth in vivo
To evaluate whether the coexpression of Caspy2 and IL15 could exert more effective tumor suppression activity, we constructed caspy2 and IL15 genes in pVitro2, a dual gene expression vector. The intratumoral expression of Caspy2 and IL15 were measured using western blotting and ELISA assay, respectively (data not shown). Next, we evaluated the combined effects of Caspy2 and IL15 coexpression on tumor growth. The overall effects of treatments on tumor growth were analyzed by measuring tumor volume. Although treatment with IL15 or Caspy2 alone could significantly inhibited mice tumor cell growth (Po0.01), a significant reduction in tumor growth was observed in pIL15-Caspy2-treated mice in the CT26 and B16F10 subcutaneous tumor model (Figures 1a and c, Po0.001) . Four of 10 of the pIL15-caspy2-treated tumors in the CT26 model and 1 of 10 in the B16F10 model were eradicated after the treatment. In addition, increased survival benefits were also gained in the pIL15-caspy2 groups compared with pIL15 or Caspy2-treated group (Figures 1b and d,  Po0.01 ). This result showed that administration of pIL15-caspy2 plasmid produced significantly additive therapeutic efficacy for suppressing tumor growth in mice.
Inhibition of 4T1 lung metastases by coexpression of IL15 and Caspy2 in vivo It is known that metastatic cancer is a result of not only alterations of gene expression within tumor cells but also the complex interaction between the host environment and metastatic tumor cells. 27 As in our model, we used the 4T1 murine metastatic breast cancer cells, which can metastasize to the lung with high frequency in BALB/c mice as early as 2 weeks after inoculation. 25, 28 Based on these findings, when the 4T1 tumor volume reached 2000 mm 3 in the current study, mice were statistically regarded as imminent deaths and killed. The metastatic lung nodules were counted under a dissecting microscope. A significant reduction in the number of tumor metastasis nodules was seen in mice treated with pIL15-caspy2 in comparison with pIL15 or pCaspy2-treated groups (Figures 2a and b, Po0.01 ). H&E staining of lung tissue sections also showed that the lung treated with pIL15-Caspy2 had much smaller nodules, and most of the lung was free of tumor ( Figure 2c ).
Induction of T-cell infiltration by coexpression of IL15 and Caspy2 in vivo
The T-cell infiltration in tumor tissues was evaluated by using H&E and immunofluorescence staining of tumor tissue with anti CD8 þ antibody. Increased local necrosis was found in both CT26 and B16F10 tumors from pIL15-caspy2-treated mice (data not shown). Abundant lymphocytes were observed at the margins and local interspaces of tumor tissues from some pIL15-caspy2-treated mice (Figure 3a) . Anti-CD8 þ monoclonal antibody staining showed that CD8 þ T-cell infiltration was significant enhanced in pIL15-Caspy2-treated group as compared with that in the pCaspy2-or pIL15-treated group (Figure 3b) .
To further document specific CTLs responses, lymphocytes were isolated from spleen and lactate dehydrogenase assay was performed. CD8
þ T-cells isolated from 5% GS treated animals did not demonstrate any lytic activity against CT26 cells, whereas CD8 þ T-cells isolated from mice treated with IL15 alone or in combination with Caspy2 showed significant lytic activity against CT26 cells in an effector:tumor cell ratio-dependent manner (Figure 3c ). Moreover, CTLs activity could be impaired by in vitro deletion of CD8 þ T lymphocytes cells, whereas deletion of NK or CD4 þ could only partially inhibit the CTLs activity in the CT26 cells (Figure 3d ). These findings indicate the pIL15-Caspy2 inducted specific CTLs activity is mainly through CD8 þ T lymphocytes.
Caspy2 modulate IL15-induced cytokine secretion
To further understand the mechanism of Caspy2 and IL15 underline the extraordinary antitumor efficiency, we detected the early intratumor expression of cytokines, including TNF-a, IL10 and IFN-g, after treatment. Mice treated with IL15 demonstrated increased IFN-g and TNF-a secretion compared with the control groups (Po0.05) (Figure 4 ). The combination of Caspy2 to IL15 resulted in further increases in IFN-g and TNF-a secretion. Consistent with previous studies, the expression of IL10 was upregulated in the pIL15-treated group. However, when combination with Caspy2, the intratumor expression of IL10 was significantly inhibited (Po0.05). Caspy2 alone had no significant effect on IFN-g, TNF-a and IL10 secretion compared with control groups.
Inhibition of cell proliferation and induction of apoptosis by the administration of pCaspy2-IL15 in vivo TUNEL assay and cleaved caspase-3 immunostaining were carried out to detect apoptosis within the tumors. Apoptosis cells were widely distributed in pCaspy2-treated tumor tissue versus control groups. Moreover, an apparent increase in the number of apoptotic cells was observed within the tumors from the pIL15-Caspy2 group. The results showed that the combined treatment of IL15 and Caspy2 was clearly more potent in inducing tumor cell apoptosis relative to monotherapy groups (Figures 5a and b , Po0.05). Tumor Cell proliferation was also evaluated by using Ki67 staining. The expression of Ki67 was dramatically reduced in the pIL15-Caspy2-treated group compared with other groups (Figure 5c , Po0.05).
Tumor cell rechallenge
To examine whether a long-term tumor-specific protective immunity was established by the treatment with pIL15-Caspy2, the long-term surviving mice were rechallenged subcutaneously, 90 days after first injection of CT26, with parental CT26 or irrelevant syngeneic 4T1 tumor. The results showed that detectable flank tumors were not observed when inoculation of CT26 tumor cells into previously pIL15-Caspy2-treated mice and all the mice survived healthily. However, when these mice were inoculated with 4T1, the tumors grew vigorously (Figures 6a and b) . In the CT26 model, animals treated with caspy2 and IL15 were 'cured' and exhibited long-term protection against the parental tumor rechallenge. These observations suggest that the treatment of established CT26 tumor model with caspy2 and IL15 gene resulted in the development of a specific long-term protective immune response. These findings further document that Caspy2-and IL15-mediated immune responses are required to completely eradicate established tumors and to prevent relapse.
Function of T-cell subsets in vivo
To further confirm that Caspy2 enhanced immune responses of IL15 in vivo, we performed the same treatment in CT26-bearing nude mice (n ¼ 5) and found that pIL15-Caspy2 treatment did not result in complete regression of established tumors in spite of significant tumor inhibition (Figure 6c) . Furthermore, the therapeutic effects of combination treat were significantly attenuated in the CT26 tumor model when depleted of CD8 þ T cells (Figure 6d) . Moreover, treatment with monoclonal antibody against CD4
þ T cells and NK cells also has effect on the antitumor activity. Therefore, the antitumor responses induced by IL15 and Caspy2 were dependent on CD8 þ cytotoxic T cells, CD4 þ helper T cells as well as NK cells. immunoregulatory responses. To eradicate the tumor and avoid re-growth of escape variants, it is generally thought that it is necessary to simultaneously attack the tumors by several different pathways. 29 Therefore, combination regimens are becoming a common practice in oncology. IL15 as monotherapy may suffer from the potential limitations imposed by increasing expression of negative regulatory cytokine. 14, 15 Thus, for IL15, its optimal usage will most likely be in combination with other antitumor therapies. Synergy might be obtained when combining with other immune therapies or with therapies that induce tumor apoptosis and local antitumor immune responses. In a previous study, we have demonstrated that Caspy2 (as a foreign antigen) can modify the apoptotic tumor cells and enhance the weak immune responses against the endogenous tumor antigen of the tumor cells. In this regard, we wonder whether gene therapy with Caspy2 and IL15 will have enhanced antitumor effect.
DISCUSSION
In the present study, we found that coexpression of Caspy2 and IL15 could significantly inhibit the tumor growth and metastasis. Previous studies have shown that Caspy2 as a foreign antigen in tumor cells could improve antitumor immunity through the acquisition of tumor-associated antigens from apoptotic tumor cells and IL15 appeared to attract CD8 þ T lymphocytes and NK cells to tumor tissues to enhance the antitumor immunity effect. 23 Therefore, we detected the infiltration of CD8 þ T cell in tumor tissues and cytotoxicity of T lymphocytes isolated from spleen. A significant increase in the infiltration of CD8 þ T lymphocytes and specific CTLs was observed in pIL15-Caspy2-treated tumorbearing mice. These results suggested that the combination treatment might activate specific cellular and humoral immunity. Furthermore, depletion of CD8 þ , CD4 þ T cells or NK cells with their mAbs attenuated pIL15-Caspy2-mediated antitumor effects both in vitro and in vivo , which indicated the antitumor immunity was dependent on CD8 þ cytotoxic T cells, CD4 þ helpers as well as NK cells. Another relevant finding of the present investigation is that the combined therapeutic approach generated a protective antitumor immune response that was long lasting. Thus, the combined approach serves a dual purpose to initiate the killing of tumor cells and to promote the effective immunization, and the acquisition of antitumor memory by the tumor-bearing host, which will hopefully bring about tumor cure. We also found significant downregulation of IL10 in pIL15-Caspy2-treated groups at an early stage. The underlying mechanism is unknown; IL10 within tumors is thought to promote CD4 þ
CD25
À T cells to transform CD4 þ CD25 þ regulatory T cells. Given that Caspy2 can chemoattract T cells into the tumor site, 23 we detected infiltration of CD4 þ T cells within tumors and did not observe obvious infiltration of CD4 þ T cells in all groups (data not shown). This can also explain the lack of obvious increase of CD4 Th1-and Th2-type cytokines within tumors. Nevertheless, the decrease in IL10 may attenuate IL10-mediated immune suppression and reduces generation of CD4 þ CD25 þ regulatory T cell. Therefore, Caspy2 could avoid the immunosuppressive effects of IL10 induced by IL15 monotherapy, but also improve antitumor immunity through the acquisition of tumor-associated antigens from apoptotic tumor cells. This may in part explain the result that combined treatment with IL15 and Caspy2 induced more potent CTLs activity in homogeneous tumor cells as compared with the single treatment. Moreover, upregulated expression of IFN-g and TNF-a was found in pIL15-Caspy2-treated mice compared with pIL15-treated mice. Those results indicated that Caspy2 could enhance the IL15-initiated specific antitumor immune response.
We have demonstrated that Caspy2 could show caspase3-like activity associated with apoptosis in mammalian cells. Caspase 3, which is involved extensively in the execution of apoptosis and the proteolytic cleavage of subcellular substrates, results in the features seen in this form of cell death, including DNA fragmentation. 30 Thus, we can infer that the induction of apoptosis might contribute to the antitumor efficiency of the combined treatment. Immunohistochemical analysis showed that there were more apoptosis cells in the tumor tissues from pIL15-Caspy2-treated group compared with pCaspy2-treated group (Po0.05). Therefore, Caspy2-triggered apoptosis might further contribute to the antitumor efficiency of the combined therapy.
Taken together, these findings in our present study may provide a new strategy for the treatment of tumors both through the induction of apoptosis and tumor-specific immune response by the treatment with the plasmid encoding caspy2 and IL15. This dual effect resulted in better therapeutic efficacy. We think that this strategy should have the potential to be developed into a useful method for treatment of tumor.
